Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review.

PMID:
24067998
2.

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.

Lung Cancer. 2011 Oct;74(1):132-8. doi: 10.1016/j.lungcan.2011.01.024. Epub 2011 Mar 1.

PMID:
21367480
3.
4.

Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.

Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH.

Lung Cancer. 2013 Jul;81(1):102-8. doi: 10.1016/j.lungcan.2013.03.002. Epub 2013 Mar 22.

PMID:
23523421
5.
6.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

7.

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.

Lung Cancer. 2012 Oct;78(1):92-9. doi: 10.1016/j.lungcan.2012.07.009. Epub 2012 Aug 11.

PMID:
22889494
8.
9.

[Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].

Duan JC, Wu MN, Zhao J, An TT, Yang L, Bai H, Wang ZJ, Zhuo ML, Wang SH, Wang YY, Liu XH, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2012 Feb;35(2):97-101. Chinese.

PMID:
22455964
10.

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.

Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2013 Jan;8(1):19-30. doi: 10.1097/JTO.0b013e31827628ff.

11.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.

J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.

PMID:
23835707
12.

[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].

Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Mar;36(3):162-8. Chinese.

PMID:
23856136
13.

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.

Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N.

Chemotherapy. 2012;58(4):313-20. doi: 10.1159/000343048. Epub 2012 Nov 7.

PMID:
23147191
15.

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

16.

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K.

Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12.

PMID:
20061047
17.

Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.

Wang T, Chuan Pan C, Rui Yu J, Long Y, Hong Cai X, De Yin X, Qiong Hao L, Li Luo L.

PLoS One. 2013 Sep 10;8(9):e74284. doi: 10.1371/journal.pone.0074284. eCollection 2013.

18.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, Park K, Ahn MJ.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.

PMID:
26124486
19.

Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF.

J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29.

PMID:
23109689
20.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

Supplemental Content

Support Center